1
|
Zhang J, Jing N, Fan X, Tang X. Photoregulation of Gene Expression with Amantadine‐Modified Caged siRNAs through Host–Guest Interactions. Chemistry 2020; 26:14002-14010. [DOI: 10.1002/chem.202003084] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2020] [Revised: 07/16/2020] [Indexed: 12/14/2022]
Affiliation(s)
- Jinhao Zhang
- State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Peking University No. 38 Xueyuan Rd. 100191 Beijing P.R. China
| | - Nannan Jing
- State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Peking University No. 38 Xueyuan Rd. 100191 Beijing P.R. China
| | - Xinli Fan
- State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Peking University No. 38 Xueyuan Rd. 100191 Beijing P.R. China
| | - Xinjing Tang
- State Key Laboratory of Natural and Biomimetic Drugs School of Pharmaceutical Sciences Peking University No. 38 Xueyuan Rd. 100191 Beijing P.R. China
| |
Collapse
|
2
|
Barrett GL, Naim T, Trieu J, Huang M. In vivo knockdown of basal forebrain p75 neurotrophin receptor stimulates choline acetyltransferase activity in the mature hippocampus. J Neurosci Res 2016; 94:389-400. [DOI: 10.1002/jnr.23717] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2015] [Revised: 12/15/2015] [Accepted: 01/11/2016] [Indexed: 11/09/2022]
Affiliation(s)
- Graham L. Barrett
- Department of Physiology; University of Melbourne; Melbourne Victoria Australia
| | - Timur Naim
- Department of Physiology; University of Melbourne; Melbourne Victoria Australia
| | - Jennifer Trieu
- Department of Physiology; University of Melbourne; Melbourne Victoria Australia
| | - Mengjie Huang
- Department of Physiology; University of Melbourne; Melbourne Victoria Australia
| |
Collapse
|
3
|
Inhibition of fibroblast growth factor receptor 1 endocytosis promotes axonal branching of adult sensory neurons. Neuroscience 2011; 188:13-22. [PMID: 21575685 DOI: 10.1016/j.neuroscience.2011.04.064] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2011] [Revised: 04/26/2011] [Accepted: 04/27/2011] [Indexed: 01/21/2023]
Abstract
Fibroblast growth factors (FGFs) promote axon growth during development and regeneration of the nervous system. Among the four types of FGF receptors (FGFRs), FGFR1 is expressed in adult sensory neurons of dorsal root ganglia (DRG), and overexpression of FGFR1 promotes FGF-2-induced elongative axon growth in vitro. Ligand-induced activation of FGFR1 is followed by endocytosis and lysosomal degradation, which leads to the termination of receptor signaling. We previously reported that the lysosomal inhibitor leupeptin enhances FGF-2-induced elongative axon growth of adult DRG neurons overexpressing FGFR1. To better understand the role of subcellular localization of FGFR1 in axon growth, we analyzed the effects of inhibition of endocytosis of FGFR1 on FGF-2-induced neurite outgrowth in PC12 pheochromocytoma cells and adult DRG neurons. The endocytosis inhibitors methyl-β-cyclodextrin (MβCD) and chlorpromazine enhanced surface localization of FGFR1 in PC12 cells and DRG neurons. Furthermore, MβCD and chlorpromazine increased FGF-2-induced neurite outgrowth of PC12 cells and axonal branching of adult DRG neurons overexpressing FGFR1, whereas MβCD inhibited FGF-2-induced axonal elongation. Analysis of the signaling pathways involved in axon morphology revealed that FGF-2-induced phosphorylation of extracellular signal-regulated kinase (ERK) and Akt was increased by inhibition of FGFR1 endocytosis. Together, our results imply that inhibition of FGFR1 endocytosis by MβCD or chlorpromazine promotes FGF-2-induced axonal branching. The results of this study confirm that internalization of FGFR1 controls axon growth and morphology of adult sensory neurons via selective activation of intracellular signaling pathways.
Collapse
|
4
|
Ulloth JE, Almaguel FG, Padilla A, Bu L, Liu JW, De Leon M. Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death. Neurotoxicology 2007; 28:613-21. [PMID: 17292476 PMCID: PMC1994916 DOI: 10.1016/j.neuro.2007.01.001] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2006] [Revised: 12/21/2006] [Accepted: 01/04/2007] [Indexed: 12/17/2022]
Abstract
Cyclodextrins (CDs) are used to deliver hydrophobic molecules in aqueous environments. Methyl-beta-cyclodextrin (MbetaCD), a member of this family of molecules, has been proposed to be a good carrier to deliver fatty acids to cells in culture. This report focuses on studying the in vitro effects of MbetaCD on nerve growth factor-differentiated PC12 (NGFDPC12) cells, a tissue culture model to study neuronal survival and differentiation. The main findings are: (1) NGFDPC12 cells have normal viability when exposed to 0.12% MbetaCD but showed a significant loss in cell viability at higher concentrations; (2) NGFDPC12 cells exposed to 0.25% MbetaCD exhibit nuclear condensation, blebbing and apoptotic bodies, and whole cell lysates exhibited an increase in caspase-3-like activity and high levels of Bax and Bcl-X(L) protein expression compared to control. Cultures treated with 0.25% MbetaCD also showed cleavage of normal 21-kDa Bax protein into a 18-kDa fragment. (3) Experiments using 0.12% MbetaCD to deliver oleic acid did not affect cell viability, in contrast NGFDPC12 cultures in which 0.25% MbetaCD concentration is used exhibited similar loss of cell viability as observed with 0.25% MbetaCD alone. Treating these cultures with caspase-3 inhibitor z-VAD-fmk did not protect the cells from MbetaCD toxic effects. (4) Immortalized Schwann cells (iSC) exposed to MbetaCD 0.12% did not show loss of cell viability while 0.25% MbetaCD triggered a significant toxicity but with a different dose and time course dynamic than NGFDPC12 cells. Thus, NGFDPC12 or iSC cell cultures exposed to 0.12% MbetaCD exhibits normal viability while higher concentrations increase in cell death and apoptosis.
Collapse
Affiliation(s)
| | | | | | | | | | - Marino De Leon
- *Corresponding author address: Center for Health Disparities and Molecular Medicine, 142 Mortensen Hall, 11085 Campus Street, Loma Linda University, School of Medicine, Loma Linda CA, 92350. Tel: 909–558–8777. Fax: 909–558–0177.
| |
Collapse
|
5
|
Abstract
Cyclodextrins (CyDs) have traditionally been used for dissolving hydrophobic chemicals into aqueous media, and more recently, for inducing cholesterol efflux from lipid-laden cells as a proposed mechanism for reversal of cardiovascular disease. This review discusses the potential of delivering therapeutic oligonucleotides to solid tumours using CyD molecules. The physicochemical properties of these oligosaccharide molecules, and the barriers posed by the solid tumour itself, factors that affect may affect the uptake of oligonucleotides by CyDs, are the major foci of this review.
Collapse
Affiliation(s)
- Crispin R Dass
- Genetic Technologies Pty. Ltd., Hanover St 3065 Fitzroy Australia.
| |
Collapse
|
6
|
Epa WR, Markovska K, Barrett GL. The p75 neurotrophin receptor enhances TrkA signalling by binding to Shc and augmenting its phosphorylation. J Neurochem 2004; 89:344-53. [PMID: 15056278 DOI: 10.1111/j.1471-4159.2004.02344.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Nerve growth factor (NGF) is an important neuronal survival factor, especially during development. Optimal sensitivity of the survival response to NGF requires the presence of TrkA and the p75 neurotrophin receptor, p75(NTR). Signalling pathways used by TrkA are well established, but the mechanisms by which p75(NTR) enhances NGF signalling remain far from clear. A prevalent view is that p75(NTR) and TrkA combine to form a high-affinity receptor, but definitive evidence for this is still lacking. We therefore investigated the possibility that p75(NTR) and TrkA interact via their signal transduction pathways. Using antisense techniques to down-regulate p75(NTR) and TrkA, we found that p75(NTR) specifically enhanced phosphorylation of the 46- and 52-kDa isoforms of Shc during nerve growth factor-induced TrkA activation. p75(NTR) did not enhance tyrosine phosphorylation of other TrkA substrates. Serine phosphorylation of Akt, downstream of Shc activation, was also p75(NTR)-dependent. We consistently detected co-immunoprecipitation of p75(NTR) and Shc. These data indicate that p75(NTR) interacts with Shc physically, via a binding interaction, and functionally, by assisting its phosphorylation. Whilst providing evidence that p75(NTR) augments TrkA signal transduction, these results do not preclude the presence of a p75(NTR)-TrkA high-affinity NGF receptor.
Collapse
MESH Headings
- Adaptor Proteins, Signal Transducing
- Adaptor Proteins, Vesicular Transport/metabolism
- Animals
- Cell Differentiation/physiology
- Cell Survival/drug effects
- Cell Survival/physiology
- Dose-Response Relationship, Drug
- Down-Regulation/drug effects
- Down-Regulation/genetics
- Nerve Growth Factor/pharmacology
- Neurons/drug effects
- Neurons/metabolism
- Oligonucleotides, Antisense/drug effects
- PC12 Cells
- Phosphorylation
- Precipitin Tests
- Protein Serine-Threonine Kinases
- Proto-Oncogene Proteins/metabolism
- Proto-Oncogene Proteins c-akt
- Rats
- Receptor, Nerve Growth Factor
- Receptor, trkA/metabolism
- Receptors, Nerve Growth Factor/antagonists & inhibitors
- Receptors, Nerve Growth Factor/genetics
- Receptors, Nerve Growth Factor/metabolism
- Shc Signaling Adaptor Proteins
- Signal Transduction/drug effects
- Signal Transduction/physiology
- Src Homology 2 Domain-Containing, Transforming Protein 1
Collapse
Affiliation(s)
- W Ruwan Epa
- Physiology Department, University of Melbourne, Parkville, Victoria, Australia
| | | | | |
Collapse
|
7
|
Abstract
Oligonucleotides (ONs) are a new class of therapeutic compounds under investigation for the treatment of a variety of disease states, such as cancer and HIV, and for FDA approval of an anti-CMV retinitis antisense molecule (Vitravene trade mark, Isis Pharmaceuticals). However, these molecules are limited not only by poor cellular uptake, but also by a general lack of understanding regarding the mechanism(s) of ON cellular uptake. As a result, various delivery vehicles have been developed that circumvent the proposed mechanism of uptake, endocytosis, while improving target specific delivery and/or drug stability. This review describes various traditional and novel delivery mechanisms that have been employed to improve ON cellular delivery, cost effectiveness, and therapeutic efficacy.
Collapse
Affiliation(s)
- Melanie A Lysik
- Midwestern University, College of Pharmacy-Glendale, Department of Pharmaceutical Sciences, 19555 N 59th Avenue, Glendale, Arizona 18308, USA.
| | | |
Collapse
|
8
|
Abstract
Antisense offers a precise and specific means of knocking down expression of a target gene, and is a major focus of research in neuroscience and other areas. It has application as a tool in gene function and target validation studies and is emerging as a therapeutic technology in its own right. It has become increasingly obvious, however, that there are a number of hurdles to overcome before antisense can be used effectively in the CNS, most notably finding suitable nucleic acid chemistries and an effective delivery vehicle to transport antisense oligonucleotides (AS-ODNs) across the blood-brain barrier (BBB) to their site of action. Despite these problems, a number of potential applications of AS-ODNs in CNS therapeutics have been validated in vitro and, in some cases, in vivo. Here the authors outline available nucleic acid chemistries and review progress in the development of non-invasive delivery vehicles that may be applicable to CNS therapeutics. Further to this, they discuss a number of experimental applications of AS-ODNs to CNS research and speculate on the development of antisense techniques to treat CNS disease.
Collapse
Affiliation(s)
- Jenny Godfray
- ExpressOn BioSystems Ltd, The Logan Building, Roslin BioCentre, Roslin, Midlothian EH25 9TT, Scotland.
| | | |
Collapse
|
9
|
Abstract
The vasculature of a tumour provides the most effective route by which neoplastic cells may be reached and eradicated by drugs. The fact that a tumour's vasculature is relatively more permeable than healthy host tissue should enable selective delivery of drugs to tumour tissue. Such delivery is relevant to carrier-mediated delivery of genetic medicine to tumours. This review discusses the potential of delivering therapeutic oligonucleotides (ONs) to tumours using cationic liposomes and cyclodextrins (CyDs), and the major hindrances posed by the tumour itself on such delivery. Cationic liposomes are generally 100-200 nm in diameter, whereas CyDs typically span 1.5 nm across. Cationic liposomes have been used for the introduction of nucleic acids into mammalian cells for more than a decade. CyD molecules are routinely used as agents that engender cholesterol efflux from lipid-laden cells, thus having an efficacious potential in the management of atherosclerosis. A recent trend is to employ these oligosaccharide molecules for delivering nucleic acids in cells both in-vitro and in-vivo. Comparisons are made with other ON delivery agents, such as porphyrin derivatives (< 1 nm), branched chain dendrimers (approximately 10 nm), polyethylenimine polymers (approximately 10 nm), nanoparticles (20-1,000 nm) and microspheres (> 1 microm), in the context of delivery to solid tumours. A discourse on how the chemical and physical properties of these carriers may affect the uptake of ONs into cells, particularly in-vivo, forms a major basis of this review.
Collapse
Affiliation(s)
- Crispin R Dass
- Johnson & Johnson Research, Strawberry Hills, Australia.
| |
Collapse
|
10
|
Abstract
The aim of this contribution is to summarize recent findings on the potential use of cyclodextrins and their derivatives as carriers for oligonucleotide agents. Their peculiar properties could be exploited in such an emerging therapeutic area by virtue of their capability of interacting with cellular membranes, thus giving rise to improved cellular uptake. In particular, some specific derivatives could be considered as promising future excipients for the delivery of "naked" antisense and/or decoy oligonucleotides which are difficult to formulate with existing pharmaceutical excipients.
Collapse
Affiliation(s)
- E Redenti
- R&D Department, Chiesi Farmaceutici S.p.A., Via Palermo 26/A, 43100 Parma, Italy.
| | | | | | | |
Collapse
|
11
|
Fletcher TM. Telomerase - strategies to exploit an important chemotherapeutic target. Expert Opin Ther Targets 2001; 5:363-378. [PMID: 12540271 DOI: 10.1517/14728222.5.3.363] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Telomeres, unique protein-DNA complexes located at the chromosome ends, have important functions involving both DNA protection and cellular signalling. Telomere structure is very dynamic yet tightly controlled. One important factor is the presence of telomerase, a telomere-specific DNA polymerase activated in a majority of cancer cells. Cancer and normal cell telomeres may have dissimilar structures due to variances in telomere length, telomerase activity and levels of telomere binding proteins. In designing compounds to strictly target cancer cells, these distinctions should be investigated. Much of the recent focus has been on the development of highly effective telomerase inhibitors. Another novel group of small molecules target telomere DNA, thereby disrupting both telomerase activity and telomere structure. This class of compounds should have an immediate impact on cell growth and viability. Since many molecular characteristics of telomeres are unknown, small molecules should also be useful in probing differences in telomere dynamics unique to cancer cells.
Collapse
Affiliation(s)
- Terace M Fletcher
- National Institutes of Health, National Cancer Institute, Division of Basic Sciences, Laboratory of Receptor Biology and Gene Expression, Bethesda, MD 20892-5055, USA.
| |
Collapse
|